Ajanta Pharma Limited has reported an excellent financial performance for the year ended March 31, 2026. The company achieved a 21% growth in revenue for the fourth quarter, while full-year revenue rose by 17% to reach ₹5,453 crore. Profit after tax for the full year stood at ₹1,056 crore, reflecting a 15% increase. The company continues to maintain a strong market presence, driven by growth in branded generics, US generics, and key chronic therapeutic segments.
Financial Performance Overview
For the fourth quarter of FY 2026, Ajanta Pharma reported revenue from operations of ₹1,422 crore, a significant 21% jump compared to the same period in the previous year. The company’s full-year revenue for FY 2026 climbed to ₹5,453 crore, up from ₹4,648 crore in FY 2025. Profit after tax (PAT) for the fiscal year reached ₹1,056 crore, an 18% increase for the quarter and a 15% increase for the full year, supported by consistent margins and a healthy ROCE of 33%.
Segment-Wise Growth
The company’s branded generics business, which accounts for 68% of total sales, showed resilience and growth. The US Generic market was a standout performer, witnessing a 49% growth in the full fiscal year with sales reaching ₹1,557 crore. In India, the branded generics segment grew by 14%, driven by leadership in chronic therapies such as cardiology, dermatology, ophthalmology, and pain management. Despite some challenges in the Asia market due to geopolitical issues, the company maintained a diversified and strong global footprint across 30+ countries.
R&D and Operational Milestones
Ajanta Pharma continues to invest in innovation, with R&D expenditure increasing to ₹252 crore for the year, maintaining a 5% spend to revenue ratio. As of the end of FY 2026, the company has 49 commercialized ANDAs and 19 products awaiting approval from the US FDA. With 7 world-class manufacturing facilities in India, the company remains focused on strengthening its presence in key markets and maintaining its lead in sub-therapeutic segments through new product launches and enhanced field force productivity.
Source: BSE
